Powder containment and aseptic transfer valve specialist ChargePoint Technology is expanding its U.S. presence, following a multi-million-pound investment from LDC.
The Liverpool, UK headquartered company struck a deal with the private equity firm in January 2017 to capitalize on the strong demand for its solutions in North America, Europe and Asia. This includes the AseptiSafe and PharmaSafe product ranges, which are used to ensure the safe transfer of active pharmaceutical ingredients (APIs) in small and large scale pharmaceutical manufacturing environments.
This demand has fueled the need for the expansion of the firm’s support team within North America. A new office, based in San Francisco, brings the total number of offices globally to four with other locations including Hong Kong and New Jersey.
Chris Rombach, previously of ILC Dover, Pacific Ozone and Stedim Biotech (now part of Sartorius group) joins the team at the San Francisco office as President of ChargePoint Inc. He will be responsible for driving the growth of the entire ChargePoint offering across the U.S., Canada, Mexico and Puerto Rico. This will include the establishment of local sales operations and the creation of new roles in the U.S., as well as new reseller channels. The company has plans to double its global workforce by 2020.
“Growing our North American presence is a significant milestone for us and reflects our strategic vision to expand the company in key markets,” Chris Eccles, CEO of ChargePoint said. “Our product range and AfterCare support mean we are ideally placed to meet the increasing demand for safe containment and sterile transfer solutions. The use of split-valve technology is growing in popularity, and can offer an alternative to more cumbersome and costly containment techniques.
ChargePoint Technology’s AseptiSafe range provides increased sterility assurance for ingredient and small component transfers in aseptic processing and sterile API production. The PharmaSafe powder containment valves offer the highest level of containment performance to ensure the safe handling of potent APIs, intermediates and pharmaceutical formulations.